Advanced search
Publication Cover
Expert Opinion on Emerging Drugs Volume 13, 2008 - Issue 2
Submit an article Journal homepage
99
Views
3
CrossRef citations to date
0
Altmetric
Review

Emerging drugs in cutaneous T cell lymphoma

Dominik Sebastian Mestel Charité Universitaetsmedizin Berlin, Skin Cancer Center, Department of Dermatology and Allergy, Charitéplatz 1, DE-10117 Berlin, Germany +49 30 450 518 213; +49 30 450 518 509; [email protected]
, MD,
Chalid Assaf Charité Universitaetsmedizin Berlin, Skin Cancer Center, Department of Dermatology and Allergy, Charitéplatz 1, DE-10117 Berlin, Germany +49 30 450 518 213; +49 30 450 518 509; [email protected]
, MD,
Matthias Steinhoff Charité Universitaetsmedizin Berlin, Skin Cancer Center, Department of Dermatology and Allergy, Charitéplatz 1, DE-10117 Berlin, Germany +49 30 450 518 213; +49 30 450 518 509; [email protected]
, MD,
Marc Beyer Charité Universitaetsmedizin Berlin, Skin Cancer Center, Department of Dermatology and Allergy, Charitéplatz 1, DE-10117 Berlin, Germany +49 30 450 518 213; +49 30 450 518 509; [email protected]
, MD,
Markus Moebs Charité Universitaetsmedizin Berlin, Skin Cancer Center, Department of Dermatology and Allergy, Charitéplatz 1, DE-10117 Berlin, Germany +49 30 450 518 213; +49 30 450 518 509; [email protected]
, PhD &
Wolfram Sterry Charité Universitaetsmedizin Berlin, Skin Cancer Center, Department of Dermatology and Allergy, Charitéplatz 1, DE-10117 Berlin, Germany +49 30 450 518 213; +49 30 450 518 509; [email protected]
, MD
Pages 345-361 | Published online: 08 Jun 2008

Bibliography

  • Diamandidou E, Colome-Grimmer M, Fayad L, et al. Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis. Blood 1998;92:1150-9
  • Siegel RS, Pandolfino T, Guitart J, et al. Primary cutaneous T-cell lymphoma: review and current concepts. J Clin Oncol 2000;18:2908-25
  • Girardi M, Heald PW, Wilson LD. The pathogenesis of mycosis fungoides. N Engl J Med 2004;350:1978-88
  • Paulli M, Berti E. Cutaneous T-cell lymphomas (including rare subtypes). Current concepts. II. Haematologica 2004;89:1372-88
  • Criscione VD, Weinstock MA. Incidence of cutaneous T-cell lymphoma in the United States, 1973 – 2002. Arch Dermatol 2007;143:854-95
  • Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007;110:1713-22
  • Kim YH, Jensen RA, Watanabe GL, et al. Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis. Arch Dermatol 1996;132:1309-13
  • Whittaker SJ, Foss FM. Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma. Cancer Treat Rev 2007;33:146-60
  • Demierre MF, Gan S, Jones J, et al. Significant impact of cutaneous T-cell lymphoma on patients' quality of life. Cancer 2006;109:1799-803
  • Bachelez H, Bagot M, Beylot-Barry M, et al. Therapy algorithm for cutaneous T-cell lymphomas. Ann Dermatol Venereol 2005;132:43-44
  • Demierre MF, Foss FM, Koh HK. Proceedings of the International Consensus Conference on Cutaneous T-cell Lymphoma (CTCL) Treatment Recommendations. Boston, Massachusetts, 1 – 2 October 1994. J Am Acad Dermatol 1997;36:460-6
  • Trautinger F, Knobler R, Willemze R, et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. Eur J Cancer 2006;42:1014-30
  • Kaye FJ, Bunn PA Jr, Steinberg SM, et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 1998;321:1784-90
  • Zackheim HS, Kashani-Sabet M, Amin S. Topical corticosteroids for mycosis fungoides. Experience in 79 patients. Arch Dermatol 1998;134:949-54
  • Zackheim HS. Topical carmustine (BCNU) in the treatment of mycosis fungoides. Dermatol Ther 2003;16:299-302
  • Ramsay DL, Halperin PS, Zeleniuch-Jacquotte A. Topical mechlorethamine therapy for early stage mycosis fungoides. J Am Acad Dermatol 1988;19:684-91
  • Breneman D, Duvic M, Kuzel T, et al. Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma. Arch Dermatol 2002;138:325-32
  • Ramsay DL, Lish KM, Yalowitz CB, et al. Ultraviolet-B phototherapy for early-stage cutaneous T-cell lymphoma. Arch Dermatol 1992;128:931-3
  • Querfeld C, Rosen ST, Kuzel TM, et al. Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy. Arch Dermatol 2005;141:305-11
  • Cotter GW, Baglan RJ, Wasserman TH, et al. Palliative radiation treatment of cutaneous mycosis fungoides – a dose response. Int J Radiat Oncol Biol Phys 1983;9:1477-80
  • Jones GW, Kacinski BM, Wilson LD, et al. Total skin electron radiation in the management of mycosis fungoides: Consensus of the European Organization for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Project Group. J Am Acad Dermatol 2002;47:364-70
  • Olsen EA. Interferon in the treatment of cutaneous T-cell lymphoma. Dermatol Ther 2003;16:311-21
  • Wollina U, Dummer R, Brockmeyer NH, et al. Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. Cancer 2003;98:993-1001
  • Greiner D, Olsen EA, Petroni G. Pentostatin (2′-deoxycoformycin) in the treatment of cutaneous T-cell lymphoma. J Am Acad Dermatol 1997;36:950-5
  • Marchi E, Alinari L, Tani M, et al. Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients. Cancer 2005;104:2437-41
  • Coors EA, von den Driesch P. Treatment of erythrodermic cutaneous T-cell lymphoma with intermittent chlorambucil and fluocortolone therapy. Br J Dermatol 2000;143:127-31
  • Akpek G, Koh HK, Bogen S, et al. Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma. Cancer 1999;86:1368-76
  • Zhang C, Hazarika P, Ni X, et al. Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. Clin Cancer Res 2002;8:1234-40
  • Boehm MF, Zhang L, Badea BA, et al. Synthesis and structure-activity relationships of novel retinoid X receptor-selective retinoids. J Med Chem 1994;37:2930-41
  • Duvic M, Hymes K, Heald P, et al., Bexarotene Worldwide Study Group. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 2001;19:2456-71
  • Duvic M, Martin AG, Kim Y, et al. Worldwide Bexarotene Study Group. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol 2001;137:581-93
  • Assaf C, Bagot M, Dummer R, et al. Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion. Br J Dermatol 2006;155:261-6
  • Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006;5:769-84
  • Timmermann S, Lehrmann H, Polesskaya A, et al. Histone acetylation and disease. Cell Mol Life Sci 2001;58:728-36
  • Rasheed WK, Johnstone RW, Prince HM. Histone deacetylase inhibitors in cancer therapy. Expert Opin Investig Drugs 2007;16:659-78
  • Marchion D, Münster P. Development of histone deacetylase inhibitors for cancer treatment. Expert Rev Anticancer Ther 2007;7:583-98
  • Strevel EL, Ing DJ, Siu LL. Molecularly targeted oncology therapeutics and prolongation of the QT interval. J Clin Oncol 2007;25:3362-71
  • Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007;25:3109-15
  • Kelly WK, O'Connor OA, Krug LM, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005;23:3923-31
  • Butler LM, Agus DB, Scher HI, et al. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 2000;60:5165-70
  • Sakajiri S, Kumagai T, Kawamata N, et al. Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines. Exp Hematol 2005;33:53-61
  • Zhang C, Richon V, Ni X, et al. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. J Invest Dermatol 2005;125:1045-52
  • O'Connor OA, Heaney ML, Schwartz L, et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 2006;24:166-73
  • Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007;109:31-9
  • Duvic M, Olsen EA, Breneman D, et al. Vorinostat (suberoylanilide hydroxamic acid, SAHA) provides prolonged safety and clinical benefit to patients with advanced cutaneous T-cell lymphoma (CTCL). ASH Annual Meeting Abstracts. Blood 2007;110:2582
  • Konstantinopoulos PA, Vandoros GP, Papavassiliou AG. FK228 (depsipeptide): a HDAC inhibitor with pleiotropic anti-tumor activities. Cancer Chemother Pharmacol 2006;58:711-5
  • Bunn PA Jr, Foss FM. T-cell lymphoma cell lines (HUT102 and HUT78) established at the National Cancer Institute: history and importance to understanding the biology, clinical features, and therapy of cutaneous T-cell lymphomas (CTCL) and adult T-cell leukemia-lymphomas (ATLL). J Cell Biochem Suppl 1996;24:12-23
  • Piekarz RL, Robey RW, Zhan Z, et al. T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood 2004;103:4636-43
  • Piekarz RL, Robey R, Sandor V, et al. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 2001;98:2865-8
  • Piekarz R, Frye R, Wright J, et al. Update of the NCI multiinstitutional phase II trial of romidepsin, FK228, for patients with cutaneous or peripheral T-cell lymphoma. ASCO Meeting Abstracts. J Clin Oncol 2007;25:8027
  • Marshall JL, Rizvi N, Kauh J, et al. A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. J Exp Ther Oncol 2002;2:325-32
  • Piekarz RL, Frye AR, Wright JJ, et al. Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin Cancer Res 2006;12:3762-73
  • George P, Bali P, Annavarapu S, et al. Combination of the histone deacetylase inhibitor LNH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood 2005;105:1768-76
  • Fiskus W, Pranpat P, Bali P, et al. Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells. Blood 2006;108:645-52
  • Prince M, George D, Johnstone R, et al. LBH589, a novel deacetylase inhibitor (DACi), treatment of patients with cutaneous T-cell lymphoma (CTCL). Skin expression profiles in the first 24 h related to clinical response following therapy. Blood 2006;108:2715
  • Fisher T, Patnaik A, Bhalla K, et al. Results of cardiac monitoring during phase I trials of a novel histone deacetylase inhibitor LBH589 in patients with advanced solid tumors and hematologic malignancies. ASCO Meeting Abstracts. J Clin Oncol 2005;23:3106
  • Zhang L, Lebwohl D, Masson E, et al. Clinically relevant QTc prolongation is not associated with current dose schedules of LBH589 (panobinostat). J Clin Oncol 2008;26:332-3
  • Giles F, Fischer T, Cortes J, et al. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 2006;12:4628-35
  • Shao W, Growney JD, Feng Y, et al. Efficacy of panobinostat (LBH589) in CTCL cell lines and a murine xenograft model: defining molecular pathways of panobinostat activity in CTCL. ASH Annual Meeting Abstracts. Blood 2007;110:1375
  • Hansen M, Gimsing P, Rasmussen A, et al. A phase I study of the histone deacetylase (HDAC) inhibitor PXD101 in patients with advanced hematological tumors. ASCO Meeting Abstracts. J Clin Oncol 2007;16:3137
  • Advani R, Hymes K, Pohlman B, et al. Belinostat (PXD101) in patients with recurrent or refractory peripheral or cutaneous T-cell lymphoma: results of a phase II study. ASH Annual Meeting Abstracts. Blood 2007;110:3453
  • Kreitman RJ. Recombinant toxins for the treatment of cancer. Curr Opin Mol Ther 2003;5:44-51
  • Foss F. Clinical experience with denileukin diftitox (ONTAK). Semin Oncol 2006;33:21-5
  • Olsen E, Duvic M, Frankel A, et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001;19:376-88
  • Negro-Vilar A, Dziewanowska Z, Groves ES, et al. Efficacy and safety of denileukin diftitox (Dd) in a phase III, double-blind, placebo-controlled study of CD25+ patients with cutaneous T-cell lymphoma (CTCL).ASCO Meeting Abstracts. J Clin Oncol 2007;25:8026
  • Foss F, Duvic M, Geskin L. et al. Efficacy and safety of Denileukin Diftitox (Ontak®) in the treatment of cutaneous T-cell lymphoma (CTCL) according to CD25 status. ASH Annual Meeting Abstracts. Blood 2006;108:2712
  • Negro-Vilar A, Dziewanowska Z, Groves E, et al. Phase III study of denileukin diftitox (ONTAK®) to evaluate efficacy and safety in CD25+ and CD25- cutaneous T-cell lymphoma (CTCL). patients ASH Annual Meeting Abstracts. Blood 2006;108:696
  • Foss F, Demierre MF, DiVenuti G. A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood 2005;106:454-7
  • Villadsen LS, Skov L, Dam TN, et al. In situ depletion of CD4(+) T cells in human skin by Zanolimumab. Arch Dermatol Res 2007;298:449-55
  • Kim YH, Duvic M, Obitz E, et al. Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood 2007;109:4655-62
  • Assaf C, Sterry W. Drug evaluation: zanolimumab, a human monoclonal antibody targeted against CD4. Curr Opin Mol Ther 2007;9:197-203
  • Dearden CE, Matutes E, Catovsky D. Alemtuzumab in T-cell malignancies. Med Oncol 2002;19:27-32
  • Rowan W, Tite J, Topley P, et al. Cross-linking of the CAMPATH-1 antigen (CD-52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells. Immunology 1998;95:427-36
  • Lundin J, Osterborg A, Brittinger G, et al. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma. J Clin Oncol 1998;16:3257-63
  • Lundin J, Hagberg H, Repp JR, et al. Phase II study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sézary syndrome. Blood 2003;101:4267-72
  • Lenihan DJ, Alencar AJ, Yang D, et al. Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome. Blood 2004;104:655-8
  • Lundin J, Kennedy B, Dearden C, et al. No cardiac toxicity associated with alemtuzumab therapy for mycosis fungoides/Sézary syndrome. Blood 2005;105:4148-9
  • Bernengo MG, Quaglino P, Comessatti A, et al. Low-dose intermittent alemtuzumab in the treatment of Sézary syndrome: clinical and immunologic findings in 14 patients. Haematologica 2007;92:784-94
  • Kennedy GA, Seymour JF, Wolf M, et al. Treatment of patients with advanced mycosis fungoides and Sézary syndrome with alemtuzumab. Eur J Haematol 2003;71:250-6
  • Chauhan D, Hideshima T, Mitsiades C, et al. Proteasome inhibitor therapy in multiple myeloma. Mol Cancer Ther 2005;4:686-92
  • Sors A, Jean-Louis F, Bégué E, et al. Inhibition of I-kappa-B kinase subunit 2 in cutaneous T-cell lymphoma down-regulates nuclear factor-kappa-B constitutive activation, induces cell death, and potentiates the apoptotic response to antineoplastic chemotherapeutic agents. Clin Cancer Res 2008;14:901-11
  • Zinzani PL, Musuraca G, Tani M, et al. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol 2007;25:4293-7
  • Gabizon AA. Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res 1992;52:891-6
  • Pulini S, Rupoli S, Goteri G, et al. Pegylated liposomal doxorubicin in the treatment of primary cutaneous T-cell lymphomas. Haematologica 2007;92:686-9
  • Zinzani PL, Bendani M, Stefoni V, et al. Value of gemcitabine treatment in heavily pretreated Hodgkin's disease patients. Haematologica 2000;85:926-9
  • Dumontet C, Morschhauser F, Solal-Celigny P, et al. Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hogkin´s lymphoma. Br J Haematol 2001;113:772-8
  • Duvic M, Talpur R, Wen S, et al. Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma. Clin Lymphoma Myeloma 2006;7:51-8
  • Kazmers IS, Mitchell BS, DaDonna PE, et al. Inhibition of purine nucleoside phosphorylase by 8-aminoguanosin: selective toxicity for T-lymphocytes. Science 1981;214:1137-9
  • Bantia S, Miller PJ, Parker CD, et al. Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H) – a novel potent and orally active immunosuppressive agent. Int Immunopharmacol 2001;1:1199-210
  • Bantia S, Ananth SL, Parker CD, et al. Mechanism of inhibition of T-acute lymphoblastic leukemia cells by PNP inhibitor–BCX-1777. Int Immunopharmacol 2003;3:879-87
  • Duvic M, Forero-Torres A, Foss F, et al. Response to oral forodesine in refractory cutaneous T-cell lymphoma: interim results of a phase I/II study. ASH Annual Meeting Abstracts. Blood 2007;110:122
  • Korycka A, Blonski JZ, Robak T. Forodesine (BCX-1777, Immucillin H) – a new purine nucleoside analogue: mechanism of action and potential clinical application. Mini Rev Med Chem 2007;7:976-83
  • Thursky KA, Worth LJ, Seymour JF, et al. Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab. Br J Haematol 2006;132:3-12
  • Assaf C. Denileukin diftitox therapy for refractory mycosis fungoides. Dermatol Clin 2008;26(Suppl1):S21-2

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.